Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NCF1 | P14598 | 7/20 | 0.45 |
| ▸ | CYBB | P04839 | 1/20 | 0.45 |
| ▸ | NOX5 | Q96PH1 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10584222 | 1.00 | CYP1A2 (0.59) | CYP1A2CYP2C9CYP2C19ALDH1A1TDP1 | |
| SCHEMBL2545268 | 1.00 | CYP1A2 (0.59) | CYP1A2CYP2C9CYP2C19ALDH1A1TDP1 | |
| SCHEMBL1029928 | 0.94 | CYP1A2 (0.66) | CYP1A2CYP2C9CYP2C19ALDH1A1TDP1 | |
| SCHEMBL29684634 | 0.94 | CYP1A2 (0.66) | CYP1A2CYP2C9CYP2C19ALDH1A1TDP1 | |
| SCHEMBL17537502 | 0.90 | CYP1A2 (0.64) | CYP1A2CYP2C9CYP2C19ALDH1A1TDP1 | |
| SCHEMBL13531826 | 0.90 | CYP1A2 (0.64) | CYP1A2CYP2C9CYP2C19ALDH1A1TDP1 | |
| SCHEMBL13435256 | 0.90 | CYP1A2 (0.64) | CYP1A2CYP2C9CYP2C19ALDH1A1TDP1 | |
| SCHEMBL8869388 | 0.87 | ALDH1A1 (0.53) | CYP1A2CYP2C9CYP2C19ALDH1A1TDP1 | |
| SCHEMBL5349206 | 0.86 | L3MBTL1 (0.61) | ALDH1A1TDP1L3MBTL1LMNAKDM4E | |
| SCHEMBL4101620 | 0.86 | L3MBTL1 (0.61) | ALDH1A1TDP1L3MBTL1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10865186-B2 | Opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2020-12-15 | — | — | US | disclosed |
| EP-3074379-B1 | OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS INDIA PVT LTD (IN) | 2019-06-26 | — | — | EP | disclosed |
| US-20180362468-A1 | OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2018-12-20 | — | — | US | disclosed |
| US-10081602-B2 | Opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2018-09-25 | — | — | US | disclosed |
| US-20170253565-A1 | OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2017-09-07 | — | — | US | disclosed |
| US-9688638-B2 | Opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688638-B2 | Opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170022167-A1 | OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2017-01-26 | — | — | US | disclosed |
| US-20170022167-A1 | OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2017-01-26 | — | — | US | disclosed |
| EP-3074379-A1 | OPIOID AGONISTS AND USES THEREOF | Nektar Therapeutics (India) Pvt. Ltd. (IN) | 2016-10-05 | — | — | EP | disclosed |
| WO-2015079459-A1 | OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS (INDIA) PVT.LTD. (IN) | 2015-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253565-A1 | OPIOID AGONISTS AND USES THEREOF | OPRM1, OPRK1, OPRD1 | CYP1A2 162/4885CYP2C9 288/4885CYP2C19 277/4885 |
| US-20170022167-A1 | OPIOID AGONISTS AND USES THEREOF | OPRM1, OPRK1, OPRD1 | CYP1A2 162/4885CYP2C9 288/4885CYP2C19 277/4885 |
| US-20180362468-A1 | OPIOID AGONISTS AND USES THEREOF | OPRM1, OPRK1, OPRD1 | CYP1A2 162/4885CYP2C9 288/4885CYP2C19 277/4885 |
| US-10865186-B2 | Opioid agonists and uses thereof | OPRM1, OPRK1, OPRD1 | CYP1A2 162/4885CYP2C9 288/4885CYP2C19 277/4885 |
| US-10081602-B2 | Opioid agonists and uses thereof | OPRM1, OPRK1, OPRD1 | CYP1A2 162/4885CYP2C9 288/4885CYP2C19 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.